for Journals by Title or ISSN
for Articles by Keywords
help
  Subjects -> MEDICAL SCIENCES (Total: 6895 journals)
    - ALLERGOLOGY AND IMMUNOLOGY (175 journals)
    - ANAESTHESIOLOGY (79 journals)
    - CARDIOVASCULAR DISEASES (277 journals)
    - CHIROPRACTIC, HOMEOPATHY, OSTEOPATHY (19 journals)
    - COMMUNICABLE DISEASES, EPIDEMIOLOGY (190 journals)
    - DENTISTRY (228 journals)
    - DERMATOLOGY AND VENEREOLOGY (132 journals)
    - EMERGENCY AND INTENSIVE CRITICAL CARE (84 journals)
    - ENDOCRINOLOGY (127 journals)
    - EXPERIMENTAL MEDICINE, LABORATORY TECHNIQUE (80 journals)
    - FORENSIC SCIENCES (30 journals)
    - GASTROENTEROLOGY (145 journals)
    - GERONTOLOGY AND GERIATRICS (111 journals)
    - HEMATOLOGY (131 journals)
    - HYPNOSIS (4 journals)
    - INTERNAL MEDICINE (117 journals)
    - MEDICAL GENETICS (57 journals)
    - MEDICAL SCIENCES (1935 journals)
    - NURSES AND NURSING (273 journals)
    - OBSTETRICS AND GYNECOLOGY (163 journals)
    - ONCOLOGY (322 journals)
    - OPHTHALMOLOGY AND OPTOMETRY (111 journals)
    - ORTHOPEDICS AND TRAUMATOLOGY (117 journals)
    - OTORHINOLARYNGOLOGY (57 journals)
    - PATHOLOGY (94 journals)
    - PEDIATRICS (228 journals)
    - PHYSICAL MEDICINE AND REHABILITATION (123 journals)
    - PSYCHIATRY AND NEUROLOGY (682 journals)
    - RADIOLOGY AND NUCLEAR MEDICINE (162 journals)
    - RESPIRATORY DISEASES (81 journals)
    - RHEUMATOLOGY (58 journals)
    - SPORTS MEDICINE (66 journals)
    - SURGERY (310 journals)
    - UROLOGY, NEPHROLOGY AND ANDROLOGY (127 journals)

GASTROENTEROLOGY (145 journals)                     

Showing 1 - 0 of 0 Journals sorted alphabetically
Abdominal Imaging     Hybrid Journal   (Followers: 12)
Acta Endoscopica     Hybrid Journal  
Acta Gastroenterologica Latinoamericana     Open Access   (Followers: 2)
Actualités Odonto-Stomatologiques     Open Access   (Followers: 3)
Advances in Diabetes and Metabolism     Open Access   (Followers: 6)
Advances in Digestive Medicine     Open Access   (Followers: 1)
Advances in Hepatology     Open Access   (Followers: 1)
AJP Gastrointestinal and Liver Physiology     Full-text available via subscription   (Followers: 4)
Akademik Gastroenteroloji Dergisi     Open Access  
Alimentary Pharmacology & Therapeutics     Hybrid Journal   (Followers: 40)
Alimentary Pharmacology & Therapeutics Symposium Series     Hybrid Journal   (Followers: 5)
American Journal of Gastroenterology Supplements     Full-text available via subscription   (Followers: 7)
American Journal of Gastroenterology, The     Hybrid Journal   (Followers: 89)
Arab Journal of Gastroenterology     Full-text available via subscription   (Followers: 3)
Arquivos de Gastroenterologia     Open Access   (Followers: 1)
Australian and New Zealand Continence Journal     Full-text available via subscription   (Followers: 3)
Avances en Odontoestomatologia     Open Access  
Best Practice & Research Clinical Gastroenterology     Full-text available via subscription   (Followers: 10)
BMC Gastroenterology     Open Access   (Followers: 13)
BMJ Open Diabetes Research & Care     Open Access   (Followers: 13)
BMJ Open Gastroenterology     Open Access   (Followers: 3)
Canadian Journal of Gastroenterology & Hepatology     Open Access   (Followers: 3)
Case Reports in Gastrointestinal Medicine     Open Access   (Followers: 3)
Case Reports in Hepatology     Open Access  
Cellular and Molecular Gastroenterology and Hepatology     Open Access   (Followers: 1)
Clinical and Experimental Gastroenterology     Open Access   (Followers: 4)
Clinical and Molecular Hepatology     Open Access   (Followers: 1)
Clinical and Translational Gastroenterology     Open Access   (Followers: 3)
Clinical Diabetes     Full-text available via subscription   (Followers: 28)
Clinical Gastroenterology and Hepatology     Hybrid Journal   (Followers: 26)
Clinical Journal of Gastroenterology     Hybrid Journal   (Followers: 12)
Clinical Medicine Insights : Gastroenterology     Open Access   (Followers: 5)
Clinics and Research in Hepatology and Gastroenterology     Hybrid Journal   (Followers: 8)
Clinics in Liver Disease     Full-text available via subscription   (Followers: 5)
Colon & Rectum     Hybrid Journal   (Followers: 3)
coloproctology     Hybrid Journal   (Followers: 1)
Colorectal Disease     Hybrid Journal   (Followers: 12)
Current Colorectal Cancer Reports     Hybrid Journal   (Followers: 2)
Current Diabetes Reports     Hybrid Journal   (Followers: 23)
Current Gastroenterology Reports     Hybrid Journal   (Followers: 5)
Current Hepatitis Reports     Hybrid Journal   (Followers: 9)
Current Opinion in Gastroenterology     Hybrid Journal   (Followers: 10)
Current Treatment Options in Gastroenterology     Hybrid Journal   (Followers: 7)
Der Gastroenterologe     Hybrid Journal   (Followers: 1)
Diabetes     Full-text available via subscription   (Followers: 281)
Diabetes Spectrum     Full-text available via subscription   (Followers: 7)
Diagnostic and Therapeutic Endoscopy     Open Access  
Digestion     Full-text available via subscription   (Followers: 7)
Digestive and Liver Disease     Hybrid Journal   (Followers: 12)
Digestive and Liver Disease Supplements     Full-text available via subscription   (Followers: 4)
Digestive Diseases     Full-text available via subscription   (Followers: 24)
Digestive Diseases and Sciences     Hybrid Journal   (Followers: 4)
Digestive Endoscopy     Hybrid Journal   (Followers: 4)
Diseases of the Colon & Rectum     Full-text available via subscription   (Followers: 21)
Diseases of the Esophagus     Hybrid Journal   (Followers: 2)
Dysphagia     Hybrid Journal   (Followers: 79)
Endoscopia     Open Access  
Endoscopy     Hybrid Journal   (Followers: 3)
Endoscopy International Open     Open Access  
Endoskopie heute     Hybrid Journal   (Followers: 1)
Esophagus     Hybrid Journal  
European Journal of Gastroenterology & Hepatology     Hybrid Journal   (Followers: 17)
Evidence-Based Gastroenterology     Full-text available via subscription   (Followers: 5)
Expert Review of Gastroenterology and Hepatology     Full-text available via subscription   (Followers: 6)
Frontline Gastroenterology     Full-text available via subscription   (Followers: 3)
Gastric Cancer     Hybrid Journal   (Followers: 1)
Gastroenterologia Kliniczna. Postępy i Standardy     Open Access  
Gastroenterología y Hepatología     Full-text available via subscription  
Gastroenterología y Hepatología Continuada     Full-text available via subscription  
Gastroenterologie up2date     Hybrid Journal   (Followers: 2)
Gastroenterology     Hybrid Journal   (Followers: 111)
Gastroenterology and Hepatology from bed to bench     Open Access   (Followers: 4)
Gastroenterology Clinics of North America     Full-text available via subscription   (Followers: 8)
Gastroenterology Insights     Open Access   (Followers: 4)
Gastroenterology Report     Open Access   (Followers: 2)
Gastroenterology Research     Open Access   (Followers: 5)
Gastroenterology Research and Practice     Open Access   (Followers: 4)
Gastrointestinal Cancer : Targets and Therapy     Open Access   (Followers: 2)
Gastrointestinal Endoscopy     Hybrid Journal   (Followers: 20)
Gastrointestinal Endoscopy Clinics of North America     Full-text available via subscription   (Followers: 5)
Gastrointestinal Intervention     Full-text available via subscription  
GE Portuguese Journal of Gastroenterology     Open Access  
Gut     Full-text available via subscription   (Followers: 134)
Gut Microbes     Full-text available via subscription   (Followers: 7)
Gut Pathogens     Full-text available via subscription   (Followers: 4)
Hepatic Medicine: Evidence and Research     Open Access   (Followers: 4)
Hepatitis B Annual     Open Access   (Followers: 3)
Hepatitis Monthly     Open Access   (Followers: 4)
Hepatitis Research and Treatment     Open Access   (Followers: 6)
Hepatology     Hybrid Journal   (Followers: 32)
Hepatology International     Hybrid Journal   (Followers: 4)
Hepatology Research     Hybrid Journal   (Followers: 13)
HPB: The official journal of the International Hepato Pancreato Biliary Association     Hybrid Journal   (Followers: 2)
Indian Journal of Gastroenterology     Open Access   (Followers: 2)
Inflammatory Bowel Diseases     Hybrid Journal   (Followers: 43)
Info Diabetologie     Full-text available via subscription  
International Journal of Celiac Disease     Open Access   (Followers: 1)
International Journal of Colorectal Disease     Hybrid Journal   (Followers: 10)
International Journal of Hepatology     Open Access   (Followers: 2)
International Journal of Stomatological Research     Open Access  
Journal Africain d'Hépato-Gastroentérologie     Hybrid Journal   (Followers: 2)
Journal of Clinical Gastroenterology     Hybrid Journal   (Followers: 12)
Journal of Coloproctology     Open Access   (Followers: 1)
Journal of Crohn's and Colitis     Hybrid Journal   (Followers: 8)
Journal of Crohn's and Colitis Supplements     Full-text available via subscription   (Followers: 2)
Journal of Diabetes Research and Clinical Metabolism     Open Access  
Journal of Digestive Diseases     Hybrid Journal   (Followers: 5)
Journal of Digestive Endoscopy     Open Access   (Followers: 2)
Journal of Gastroenterology     Hybrid Journal   (Followers: 13)
Journal of Gastroenterology and Hepatology     Hybrid Journal   (Followers: 12)
Journal of Gastroenterology and Hepatology Research     Open Access   (Followers: 2)
Journal of Gastrointestinal Cancer     Hybrid Journal   (Followers: 3)
Journal of Gastrointestinal Oncology     Open Access   (Followers: 1)
Journal of Hepato-Biliary-Pancreatic Sciences     Hybrid Journal   (Followers: 3)
Journal of Hepatology     Hybrid Journal   (Followers: 16)
Journal of Obesity and Metabolic Research     Open Access  
Journal of Social Health and Diabetes     Open Access  
Journal of Viral Hepatitis     Hybrid Journal   (Followers: 11)
Kidney Disease and Transplantation     Open Access  
Liver International     Hybrid Journal   (Followers: 9)
Nature Reviews Gastroenterology & Hepatology     Full-text available via subscription   (Followers: 23)
Nederlands Tijdschrift voor Diabetologie     Hybrid Journal  
Neurogastroenterology & Motility     Hybrid Journal   (Followers: 3)
Nigerian Journal of Gastroenterology and Hepatology     Full-text available via subscription  
Obesity Science & Practice     Open Access  
Oncology, Gastroenterology and Hepatology Reports     Open Access   (Followers: 1)
Open Journal of Gastroenterology     Open Access   (Followers: 5)
Perspectives on Swallowing and Swallowing Disorders (Dysphagia)     Full-text available via subscription   (Followers: 15)
Revista Brasileira de Coloproctologia     Open Access  
Revista de Gastroenterología de México     Open Access  
Revista de Gastroenterología de México (English Edition)     Open Access  
Revista Española de Enfermedades Digestivas     Open Access   (Followers: 1)
Revue de Stomatologie et de Chirurgie Maxillo-faciale     Full-text available via subscription   (Followers: 1)
Saudi Journal of Gastroenterology     Open Access   (Followers: 3)
Saudi Journal of Obesity     Open Access  
Scandinavian Journal of Gastroenterology     Hybrid Journal   (Followers: 10)
Seminars in Liver Disease     Hybrid Journal   (Followers: 6)
South African Gastroenterology Review     Full-text available via subscription   (Followers: 1)
Techniques in Coloproctology     Hybrid Journal   (Followers: 9)
Techniques in Gastrointestinal Endoscopy     Hybrid Journal   (Followers: 2)
The Lancet Diabetes and Endocrinology     Full-text available via subscription   (Followers: 48)
Therapeutic Advances in Gastroenterology     Hybrid Journal   (Followers: 5)
United European Gastroenterology Journal     Hybrid Journal   (Followers: 2)
Visible Human Journal of Endoscopy     Full-text available via subscription  
World Council of Enterostomal Therapists Journal     Full-text available via subscription  
World Journal of Gastroenterology     Full-text available via subscription  
Zeitschrift für Gastroenterologie     Hybrid Journal   (Followers: 4)

           

Journal Cover Gastroenterology Clinics of North America
  [SJR: 1.142]   [H-I: 62]   [8 followers]  Follow
    
   Full-text available via subscription Subscription journal
   ISSN (Print) 0889-8553
   Published by Elsevier Homepage  [2970 journals]
  • Forthcoming Issues
    • Abstract: Publication date: March 2016
      Source:Gastroenterology Clinics of North America, Volume 45, Issue 1




      PubDate: 2016-02-20T19:14:26Z
       
  • Autoimmune Pancreatitis
    • Abstract: Publication date: March 2016
      Source:Gastroenterology Clinics of North America, Volume 45, Issue 1
      Author(s): Kamraan Madhani, James J. Farrell

      Teaser There is an evolving understanding that autoimmune pancreatitis (AIP) is an immunoglobulin (Ig) G4 systemic disease. It can manifest as primarily a pancreatic disorder or in association with other disorders of presumed autoimmune cause. Classic clinical characteristics include obstructive jaundice, abdominal pain, and acute pancreatitis. Thus, AIP can be difficult to distinguish from pancreatic malignancy. However, AIP may respond to therapy with corticosteroids, and has a strong association with other immune mediated diseases. Although primarily a pathologic diagnosis, attempts have been made to reliably diagnose AIP clinically. AIP can be classified as either type 1 or type 2.

      PubDate: 2016-02-20T19:14:26Z
       
  • Advances in Surgical Management of Pancreatic Diseases
    • Abstract: Publication date: March 2016
      Source:Gastroenterology Clinics of North America, Volume 45, Issue 1
      Author(s): Jashodeep Datta, Charles M. Vollmer

      Teaser The surgical management of pancreatic diseases is rapidly evolving, encompassing advances in evidence-driven selection of patients amenable for surgical therapy, preoperative risk stratification, refinements in the technical conduct of pancreatic operations, and quantification of postoperative morbidity. These advances have resulted in dramatic reductions in mortality following pancreatic surgery, particularly at high-volume pancreatic centers. Surgical decision making is complex, and requires an intimate understanding of disease pathobiology, host physiology, technical considerations, and evolving trends. This article highlights key developments in the contemporary surgical management of pancreatic diseases.

      PubDate: 2016-02-20T19:14:26Z
       
  • Index
    • Abstract: Publication date: March 2016
      Source:Gastroenterology Clinics of North America, Volume 45, Issue 1




      PubDate: 2016-02-20T19:14:26Z
       
  • The Role of Endoscopic Retrograde Cholangiopancreatography in Management
           of Pancreatic Diseases
    • Abstract: Publication date: March 2016
      Source:Gastroenterology Clinics of North America, Volume 45, Issue 1
      Author(s): Brian P. Riff, Vinay Chandrasekhara

      Teaser Endoscopic retrograde cholangiopancreatography is an effective platform for a variety of therapies in the management of benign and malignant disease of the pancreas. Over the last 50 years, endotherapy has evolved into the first-line therapy in the majority of acute and chronic inflammatory diseases of the pancreas. As this field advances, it is important that gastroenterologists maintain an adequate knowledge of procedure indication, maintain sufficient procedure volume to handle complex pancreatic endotherapy, and understand alternate approaches to pancreatic diseases including medical management, therapy guided by endoscopic ultrasonography, and surgical options.

      PubDate: 2016-02-20T19:14:26Z
       
  • Imaging of the Pancreas
    • Abstract: Publication date: March 2016
      Source:Gastroenterology Clinics of North America, Volume 45, Issue 1
      Author(s): Ming-ming Xu, Amrita Sethi

      Teaser The evaluation of pancreatic lesions, from solid pancreatic masses to pancreatic cysts, remains a clinical challenge. Although cross-sectional imaging remains the cornerstone of the initial evaluation of an indeterminate pancreatic lesion, advances in imaging with the advent of endoscopic ultrasound scan, elastography, contrast-enhanced endoscopic ultrasound scan, and probe-based confocal laser endomicroscopy have allowed us to visualize the pancreas in even higher resolution and diagnose premalignant and malignant lesions of the pancreas with improved accuracy. This report reviews the range of imaging tools currently available to evaluate pancreatic lesions, from solid tumors to pancreatic cysts.

      PubDate: 2016-02-20T19:14:26Z
       
  • Contents
    • Abstract: Publication date: March 2016
      Source:Gastroenterology Clinics of North America, Volume 45, Issue 1




      PubDate: 2016-02-20T19:14:26Z
       
  • Management of Pancreatic Diseases
    • Abstract: Publication date: March 2016
      Source:Gastroenterology Clinics of North America, Volume 45, Issue 1
      Author(s): Nuzhat A. Ahmad



      PubDate: 2016-02-20T19:14:26Z
       
  • Copyright
    • Abstract: Publication date: March 2016
      Source:Gastroenterology Clinics of North America, Volume 45, Issue 1




      PubDate: 2016-02-20T19:14:26Z
       
  • Contributors
    • Abstract: Publication date: March 2016
      Source:Gastroenterology Clinics of North America, Volume 45, Issue 1




      PubDate: 2016-02-20T19:14:26Z
       
  • Index
    • Abstract: Publication date: December 2015
      Source:Gastroenterology Clinics of North America, Volume 44, Issue 4




      PubDate: 2016-01-18T09:46:06Z
       
  • Pancreatic Cystic Neoplasms
    • Abstract: Publication date: Available online 13 January 2016
      Source:Gastroenterology Clinics of North America
      Author(s): Gyanprakash A. Ketwaroo, Koenraad J. Mortele, Mandeep S. Sawhney

      Teaser The incidence of pancreatic cystic neoplasms is rising, in part from detection through the increasing use of high-resolution cross-sectional imaging techniques. Initial diagnosis is generally based on imaging characteristics identified on computed tomography and/or MRI. Endoscopic ultrasound provides further imaging characterization and also enables fluid aspiration and analysis to additionally aid differentiation. The general approach to these lesions includes surgical intervention and/or surveillance imaging. Taking into account diverse presentations, varying malignant potential, and the uncertain natural history of some of these lesions, an evidence-based approach is limited. This article discusses recent updates in the diagnosis and management of cystic neoplasms of the pancreas.

      PubDate: 2016-01-13T08:33:04Z
       
  • Islet Cell Tumors of the Pancreas
    • Abstract: Publication date: Available online 13 January 2016
      Source:Gastroenterology Clinics of North America
      Author(s): Sunil Amin, Michelle Kang Kim

      Teaser Islet cell tumors of the pancreas, also known as pancreatic neuroendocrine tumors, constitute less than 5% of pancreatic tumors, and 7% of all neuroendocrine tumors. Most are non-functional, and patients often present with metastatic disease. Functional tumors present with distinct clinical syndromes. Accurate staging is critical as surgery is both the cornerstone of treatment, and the only hope for cure. Medical management involves treating the manifestations of hormonal excess, and using somatastatin analogues when appropriate. Systemic chemotherapy, targeted molecular therapy, and peptide receptor radiotherapy may be used for refractory disease in lieu of or as an adjunct to surgery.

      PubDate: 2016-01-13T08:33:04Z
       
  • Advances in Management of Pancreatic Diseases
    • Abstract: Publication date: Available online 13 January 2016
      Source:Gastroenterology Clinics of North America
      Author(s): Nuzhat A. Ahmad



      PubDate: 2016-01-13T08:33:04Z
       
  • Pancreas Transplantation in the Modern Era
    • Abstract: Publication date: Available online 13 January 2016
      Source:Gastroenterology Clinics of North America
      Author(s): Robert R. Redfield, Michael R. Rickels, Ali Naji, Jon S. Odorico

      Teaser The field of pancreas transplantation has evolved from an experimental procedure in the 1980s to become a routine transplant in the modern era. With short- and long-term outcomes continuing to improve and the significant mortality, quality-of-life, and end-organ disease benefits, pancreas transplantation should be offered to more patients. In this article, we review current indications, patient selection, surgical considerations, complications, and outcomes in the modern era of pancreas transplantation.

      PubDate: 2016-01-13T08:33:04Z
       
  • Screening for Pancreatic Cancer in High-risk Populations
    • Abstract: Publication date: Available online 12 January 2016
      Source:Gastroenterology Clinics of North America
      Author(s): Shilpa Grover, Kunal Jajoo

      Teaser Pancreatic adenocarcinoma is a leading cause of cancer death. Few patients are candidates for curative resection due to the late stage at diagnosis. While most pancreatic adenocarcinomas are sporadic, approximately 10% have an underlying hereditary basis. Known genetic syndromes account for only 20% of the familial clustering of pancreatic cancer cases. The majority are due to non-syndromic aggregation of pancreatic cancer cases or familial pancreatic cancer. Screening aims to identify high-risk lesions amenable to surgical resection. However, the optimal interval for screening and the management of pancreatic cancer precursor lesions detected on imaging are controversial.

      PubDate: 2016-01-13T08:33:04Z
       
  • Pancreatic Pseudocysts
    • Abstract: Publication date: Available online 13 January 2016
      Source:Gastroenterology Clinics of North America
      Author(s): Phillip S. Ge, Mikhayla Weizmann, Rabindra R. Watson

      Teaser Endoscopic drainage is the first-line therapy in the management of pancreatic pseudocysts. Before endoscopic drainage, clinicians should exclude the presence of pancreatic cystic neoplasms and avoid drainage of immature peripancreatic fluid collections or pseudoaneurysms. The indication for endoscopic drainage is not dependent on absolute cyst size alone, but on the presence of attributable signs or symptoms. Endoscopic management should be performed as part of a multidisciplinary approach in close cooperation with surgeons and interventional radiologists. Drainage may be performed either via a transpapillary approach or a transmural approach; additionally, endoscopic necrosectomy may be performed for patients with walled-off necrosis.

      PubDate: 2016-01-13T08:33:04Z
       
  • Advances in Management of Acute Pancreatitis
    • Abstract: Publication date: Available online 19 December 2015
      Source:Gastroenterology Clinics of North America
      Author(s): Nigeen H. Janisch, Timothy B. Gardner

      Teaser This article reviews advances in the management of acute pancreatitis. Medical treatment has been primarily supportive for this diagnosis, and despite extensive research efforts, there are no pharmacologic therapies that improve prognosis. The current mainstay of management, notwithstanding the ongoing debate regarding the volume, fluid type, and rate of administration, is aggressive intravenous fluid resuscitation. Although antibiotics were used consistently for prophylaxis in severe acute pancreatitis to prevent infection, they are no longer used unless infection is documented. Enteral nutrition, especially in patients with severe acute pancreatitis, is considered a cornerstone in management of this disease.

      PubDate: 2015-12-20T11:58:36Z
       
  • Hepatitis C Virus: The Next Epidemic
    • Abstract: Publication date: December 2015
      Source:Gastroenterology Clinics of North America, Volume 44, Issue 4
      Author(s): K. Rajender Reddy



      PubDate: 2015-11-21T21:34:10Z
       
  • Hepatitis C: Unfolding the Challenges
    • Abstract: Publication date: December 2015
      Source:Gastroenterology Clinics of North America, Volume 44, Issue 4
      Author(s): K. Rajender Reddy



      PubDate: 2015-11-21T21:34:10Z
       
  • Epidemiology of Hepatitis C Virus
    • Abstract: Publication date: December 2015
      Source:Gastroenterology Clinics of North America, Volume 44, Issue 4
      Author(s): Norah J. Shire, Kenneth E. Sherman

      Teaser The hepatitis C virus (HCV) is a leading cause of liver-related morbidity and mortality in the United States and other parts of the world. The epidemiology of the disease is highly variable between and within countries, and strategies to deal with HCV identification and treatment must be tailored to the geographic location and the political and economic environment of the region. Although great strides have been made in improving HCV transmission risk in blood supply products, new challenges related to changing patterns of disease incidence continue to require fresh evaluation and new approaches to disease prevention.

      PubDate: 2015-11-21T21:34:10Z
       
  • Hepatitis C Virus
    • Abstract: Publication date: December 2015
      Source:Gastroenterology Clinics of North America, Volume 44, Issue 4
      Author(s): Tarik Asselah, Marc Bourlière

      Teaser Hepatitis C virus (HCV) is a major cause of chronic liver disease, with more than 170 million infected individuals worldwide. Genotype 4 is the most frequent cause of chronic hepatitis C in the Middle East and sub-Saharan Africa. It has recently spread to southern Europe. The introduction of all-oral, interferon-free regimens that combine direct-acting antivirals (DAAs) has significantly advanced HCV treatment. High efficacy rates, short treatment duration, and favorable adverse event profiles have been demonstrated with multiple regimens, both with and without ribavirin. This review discusses management of patients with HCV genotype 4 chronic hepatitis, in the era of DAAs.

      PubDate: 2015-11-21T21:34:10Z
       
  • Copyright-Page
    • Abstract: Publication date: December 2015
      Source:Gastroenterology Clinics of North America, Volume 44, Issue 4




      PubDate: 2015-11-21T21:34:10Z
       
  • Contributors
    • Abstract: Publication date: December 2015
      Source:Gastroenterology Clinics of North America, Volume 44, Issue 4




      PubDate: 2015-11-21T21:34:10Z
       
  • Contents
    • Abstract: Publication date: December 2015
      Source:Gastroenterology Clinics of North America, Volume 44, Issue 4




      PubDate: 2015-11-21T21:34:10Z
       
  • Forthcoming Issues
    • Abstract: Publication date: December 2015
      Source:Gastroenterology Clinics of North America, Volume 44, Issue 4




      PubDate: 2015-11-21T21:34:10Z
       
  • Hepatitis C Virus
    • Abstract: Publication date: Available online 1 October 2015
      Source:Gastroenterology Clinics of North America
      Author(s): Gary W. Falk



      PubDate: 2015-10-04T05:08:52Z
       
  • Hepatitis C Virus
    • Abstract: Publication date: Available online 1 October 2015
      Source:Gastroenterology Clinics of North America
      Author(s): Georg Dultz, Stefan Zeuzem

      Teaser Chronic hepatitis C virus (HCV) infection is a major public health burden in Europe, being one of the leading causes of chronic liver disease, liver cirrhosis, and hepatocellular carcinoma. Properties of the HCV disease burden are heterogeneous across the European continent, with differences in incidence, prevalence, diagnosis and treatment rates, transmission routes, and genotype distribution. Recent estimates expect an increase in HCV-related morbidity and mortality in most European countries until 2030 even when current treatment options are taken into account. The European perspective on hepatitis C virus infection is summarized herein.

      PubDate: 2015-10-04T05:08:52Z
       
  • Hepatitis C, an Eastern Perspective
    • Abstract: Publication date: Available online 16 September 2015
      Source:Gastroenterology Clinics of North America
      Author(s): Yock Young Dan, Seng Gee Lim

      Teaser HCV in the East is a complex scenario with prevalence rates of 0.5% to as high as 4.7%, and variable distributions of genotypes, with a dominance of genotype 1b in East Asia, genotype 3 in South Asia and South East Asia, and genotype 6 in Indochina. Approvals for the new oral directing antiviral agents (DAAs), in the East have been very slow, but ultimately will be achieved by 2019, consequently, pegylated interferon and ribavirin are still widely used. Nonetheless the main issues are the problems of screening and linkage to management, and the considerable barriers to access HCV care.

      PubDate: 2015-09-17T23:35:22Z
       
  • Contents
    • Abstract: Publication date: September 2015
      Source:Gastroenterology Clinics of North America, Volume 44, Issue 3




      PubDate: 2015-08-27T17:19:47Z
       
  • Copyright Page
    • Abstract: Publication date: September 2015
      Source:Gastroenterology Clinics of North America, Volume 44, Issue 3




      PubDate: 2015-08-27T17:19:47Z
       
  • Contributors
    • Abstract: Publication date: September 2015
      Source:Gastroenterology Clinics of North America, Volume 44, Issue 3




      PubDate: 2015-08-27T17:19:47Z
       
  • Forthcoming Issues
    • Abstract: Publication date: September 2015
      Source:Gastroenterology Clinics of North America, Volume 44, Issue 3




      PubDate: 2015-08-27T17:19:47Z
       
  • Helicobacter pylori
    • Abstract: Publication date: September 2015
      Source:Gastroenterology Clinics of North America, Volume 44, Issue 3
      Author(s): Gary W. Falk



      PubDate: 2015-08-27T17:19:47Z
       
  • Natural History of Hepatitis C
    • Abstract: Publication date: Available online 25 August 2015
      Source:Gastroenterology Clinics of North America
      Author(s): Shilpa Lingala, Marc G. Ghany

      Teaser Hepatitis C infection is a common cause of cirrhosis and indication for liver transplantation in the United States. The incidence of chronic hepatitis C has been declining, but rates of cirrhosis and hepatocellular carcinoma are projected to increase. The outcome of chronic hepatitis C is variable. It is estimated that 20% to 25% will develop cirrhosis over a 25-year to 30-year period. The rate of disease progression is influenced by many host, viral, and environmental factors. Few can be modified.

      PubDate: 2015-08-27T17:19:47Z
       
  • Management of Helicobacter pylori–Related Diseases
    • Abstract: Publication date: September 2015
      Source:Gastroenterology Clinics of North America, Volume 44, Issue 3
      Author(s): Akiko Shiotani, David Y. Graham



      PubDate: 2015-08-27T17:19:47Z
       
  • Immunopathogenesis of Hepatitis C Virus Infection
    • Abstract: Publication date: Available online 13 August 2015
      Source:Gastroenterology Clinics of North America
      Author(s): David E. Kaplan

      Teaser Despite advances in therapy, hepatitis C virus infection remains a major global health issue with 3 to 4 million incident cases and 170 million prevalent chronic infections. Complex, partially understood, host-virus interactions determine whether an acute infection with hepatitis C resolves, as occurs in approximately 30% of cases, or generates a persistent hepatic infection, as occurs in the remainder. Once chronic infection is established, the velocity of hepatocyte injury and resultant fibrosis is significantly modulated by immunologic as well as environmental factors. Immunomodulation has been the backbone of antiviral therapy despite poor understanding of its mechanism of action.

      PubDate: 2015-08-15T13:46:05Z
       
  • Hepatitis C
    • Abstract: Publication date: Available online 13 August 2015
      Source:Gastroenterology Clinics of North America
      Author(s): Christine K. Lee, Maureen M. Jonas

      Teaser Hepatitis C infection is a global health problem. Most infected children have not been identified. Perinatal transmission is the most common mode of acquisition. Liver disease owing to chronic hepatitis C virus (HCV) infection progresses slowly in individuals infected early in life. Serious complications rarely affect patients during childhood. Successful treatment of HCV in adults has improved and recommendations have changed. Treatment in children should be deferred until direct-acting antivirals and interferon-free regimens are available to this population. If treatment cannot be deferred, regimens including peginterferon and ribavirin can be given to children with compensated liver disease.

      PubDate: 2015-08-15T13:46:05Z
       
  • Impact of Hepatitis C Virus Infection on Hepatocellular Carcinoma
    • Abstract: Publication date: Available online 12 August 2015
      Source:Gastroenterology Clinics of North America
      Author(s): Danielle M. Tholey, Joseph Ahn

      Teaser Hepatitis C virus (HCV)–associated hepatocellular carcinoma (HCC) incidence in the United States is increasing, partly because of risk factors such as diabetes, fatty liver, hepatitis B virus, and human immunodeficiency virus coinfection. Achieving sustained virologic response (SVR) is the most significant factor in reducing HCV-associated HCC incidence. Improved SVR with the next generation of direct-acting antivirals brings hope for decreased HCC mortality. Nevertheless, surveillance for HCC remains important because HCC can still occur despite SVR, especially in cirrhotics. Individualized risk stratification through increased understanding of HCC pathogenesis and improved surveillance holds the promise for future reduction of HCC incidence.

      PubDate: 2015-08-15T13:46:05Z
       
  • Extrahepatic Manifestations of Hepatitis C Virus
    • Abstract: Publication date: Available online 12 August 2015
      Source:Gastroenterology Clinics of North America
      Author(s): Mauro Viganò, Massimo Colombo

      Teaser Chronic infection with the hepatitis C virus (HCV) is a major cause of liver disease worldwide and is also responsible for extrahepatic manifestations (EHMs) involving the skin, kidneys, salivary glands, eyes, thyroid, and immune system. Mixed cryoglobulinemia is the prototype EHM related to HCV infection. Although these HCV-related EHMs may contribute to significant rates of morbidity affecting patient's quality of life and survival, most of these complications can reverse after HCV eradication by interferon therapy. This notwithstanding, individual patients may have an irreversible injury in various organs that is not reversed by a cure of the HCV infection.

      PubDate: 2015-08-15T13:46:05Z
       
  • Treatment of Chronic Hepatitis C in Special Populations
    • Abstract: Publication date: Available online 8 August 2015
      Source:Gastroenterology Clinics of North America
      Author(s): Chalermrat Bunchorntavakul, Tawesak Tanwandee

      Teaser The management of hepatitis C virus (HCV) infection in special populations is challenging. The efficacy and safety data of the currently approved all-oral direct-acting antiviral combinations, including sofosbuvir, ledipasvir, daclatasvir, paritaprevir/ritonavir/ombitasvir plus dasabuvir (3D), and ribavirin, is compelling for use in special HCV populations, as has recently been recommended by expert guidelines. The treatment regimens and sustained virological response rates for special populations are nearly similar to those of the general HCV population. Sofosbuvir is not recommended in patients with severe renal impairment, and simeprevir and 3D regimen are not recommended for those with decompensated liver disease.

      PubDate: 2015-08-11T13:05:35Z
       
  • Current Treatment Options in Patients with Hepatitis C Virus Genotype 6
    • Abstract: Publication date: Available online 8 August 2015
      Source:Gastroenterology Clinics of North America
      Author(s): Nghia H. Nguyen, Mindie H. Nguyen

      Teaser Approximately 3% of the world’s population is chronically infected with hepatitis C virus (HCV). In some southeast Asian countries the prevalence of HCV (∼6%–7%) far exceeds that seen in the United States (1.8%). The lesser known HCV genotype 6 (HCV-6) is also common in patients from southeast Asia and the surrounding regions. Most data on direct-acting antivirals (DAAs) to date have been derived from clinical trials conducted in Western countries, where HCV-6 is rare. The standard of care for patients with HCV-6 is still pegylated interferon and ribavirin. However, data are emerging for several DAA combinations.

      PubDate: 2015-08-11T13:05:35Z
       
  • Hepatitis C Virus
    • Abstract: Publication date: Available online 11 August 2015
      Source:Gastroenterology Clinics of North America
      Author(s): Javier Ampuero, Manuel Romero-Gómez

      Teaser Hepatitis C virus (HCV) genotypes 2 and 3 have previously been classified as easy-to-treat genotypes, because sustained virologic responses (SVRs) up to 80% have been achieved with 24-week peginterferon and ribavirin. More detailed studies have shown differences between HCV genotypes 2 and 3, indicating that genotype 3 has become the most difficult-to-treat genotype. With new drugs, new challenges are emerging regarding relapse rates, the role of ribavirin, and optimal duration of therapy. Sofosbuvir remains the backbone of genotype 3 therapy, whereas this drug is not an option in patients with creatinine clearance lower than 30 mL/min.

      PubDate: 2015-08-11T13:05:35Z
       
  • Current and Evolving Treatments of Genotype 1 Hepatitis C Virus
    • Abstract: Publication date: Available online 11 August 2015
      Source:Gastroenterology Clinics of North America
      Author(s): Saleh Alqahtani, Mark Sulkowski

      Teaser Development of antiviral agents that target the hepatitis C virus (HCV) has improved the success and tolerability of treatment, especially for patients with HCV genotype 1 infection. The new treatment options mean that clinicians are better able to prevent complications from chronic HCV infection. The field of direct-acting antiviral therapies for HCV infection continues to advance at a rapid pace, and many more potential treatment regimens are being investigated. This article presents a summary of the current treatments available for patients infected with HCV genotype 1 and looks ahead to those that may play a role in the future.

      PubDate: 2015-08-11T13:05:35Z
       
  • Is There a Role for Probiotics in Helicobacter pylori Therapy'
    • Abstract: Publication date: Available online 22 July 2015
      Source:Gastroenterology Clinics of North America
      Author(s): Maria P. Dore, Elisabetta Goni, Francesco Di Mario

      Teaser The role of probiotics in Helicobacter pylori therapy remains unclear. Lactobacilli can be shown to inhibit H pylori in vitro. Some strains of Lactobacilli may exert specific antimicrobial effects. There is no strong evidence of a benefit on eradication rate when probiotics are added to a regimen. Despite promising results obtained using compounds of L reuteri and S boulardii, high-quality trials are needed to define the role of probiotics as adjuvant therapy. Variables that remain to be studied with L reuteri, currently the most promising strain, include dosage, frequency of administration, administration in relation to meals, and duration of therapy.

      PubDate: 2015-07-26T07:14:56Z
       
  • Helicobacter pylori: New Thoughts and Practices
    • Abstract: Publication date: Available online 22 July 2015
      Source:Gastroenterology Clinics of North America
      Author(s): Akiko Shiotani, David Y. Graham



      PubDate: 2015-07-26T07:14:56Z
       
  • Molecular Approaches to Identify Helicobacter pylori Antimicrobial
           Resistance
    • Abstract: Publication date: Available online 23 July 2015
      Source:Gastroenterology Clinics of North America
      Author(s): Francis Mégraud, Lucie Bénéjat, Esther Nina Ontsira Ngoyi, Philippe Lehours

      Teaser Antimicrobial susceptibility testing is needed to adapt Helicobacter pylori treatment to obtain the best results. Beside the standard phenotypic methods, molecular methods are increasingly used. The value of these molecular tests is that they are quick, independent of the transport conditions, easy to standardize, and commercial kits are available. In this article, these methods are reviewed, focusing on the determination of H pylori resistance to macrolides and fluoroquinolones, and mentioning also the methods used for tetracycline and rifampin.

      PubDate: 2015-07-26T07:14:56Z
       
  • How to Effectively Use Bismuth Quadruple Therapy The Good, the Bad, and
           the Ugly
    • Abstract: Publication date: Available online 19 June 2015
      Source:Gastroenterology Clinics of North America
      Author(s): David Y. Graham , Sun-Young Lee

      Teaser Bismuth triple therapy was the first effective Helicobacter pylori eradication therapy. The addition of a proton pump inhibitor helped overcome metronidazole resistance. Its primary indication is penicillin allergy or when clarithromycin and metronidazole resistance are both common. Resistance to the primary first-line therapy have centered on complexity and difficulties with compliance. Understanding regional differences in effectiveness remains unexplained because of the lack of studies including susceptibility testing and adherence data. We discuss regimen variations including substitutions of doxycycline, amoxicillin, and twice a day therapy and provide suggestions regarding what is needed to rationally and effectively use bismuth quadruple therapy.

      PubDate: 2015-06-21T03:05:03Z
       
  • Practical Aspects in Choosing a Helicobacter pylori Therapy
    • Abstract: Publication date: Available online 19 June 2015
      Source:Gastroenterology Clinics of North America
      Author(s): Javier Molina-Infante , Akiko Shiotani

      Teaser Cure rates greater than 90%-95% should be expected with an antimicrobial therapy for Helicobacter pylori infection. Standard triple therapy does not guarantee these efficacy rates in most settings worldwide anymore. The choice of eradication regimen should be dictated by factors that can predict the outcome: (1) H. pylori susceptibility; (2) patients' history of prior antibiotic therapy; and (3) local data, either resistance patterns or clinical success. Currently, the preferred first-line choices are 14-day bismuth quadruple and 14-day non-bismuth quadruple concomitant therapy. Bismuth quadruple (if not used previously), fluoroquinolone-, furazolidone- and rifabutin-containing regimens might be effective rescue treatments.

      PubDate: 2015-06-21T03:05:03Z
       
  • Diagnosis of Helicobacter pylori Infection in the Proton Pump Inhibitor
           Era
    • Abstract: Publication date: Available online 20 June 2015
      Source:Gastroenterology Clinics of North America
      Author(s): Xavier Calvet

      Teaser Proton pump inhibitors (PPI) are a major cause of false-negative Helicobacter pylori test results. Detecting PPI use and stopping it 2 weeks before testing is the preferred approach to improve the reliability of H pylori diagnostic tests. Immunoblot and molecular methods may be useful for the detection of H pylori infection in difficult cases. When conventional tests are negative and eradication is strongly indicated, empirical H pylori treatment should be considered. In this article, an updated critical review of the usefulness of the various invasive and noninvasive tests in the context of extensive PPI use is provided.

      PubDate: 2015-06-21T03:05:03Z
       
 
 
JournalTOCs
School of Mathematical and Computer Sciences
Heriot-Watt University
Edinburgh, EH14 4AS, UK
Email: journaltocs@hw.ac.uk
Tel: +00 44 (0)131 4513762
Fax: +00 44 (0)131 4513327
 
About JournalTOCs
API
Help
News (blog, publications)
JournalTOCs on Twitter   JournalTOCs on Facebook

JournalTOCs © 2009-2015